Granules India soars on getting EU GMP certificate for Unit V facility in Andhra Pradesh
Granules India is currently trading at Rs. 559.00, up by 23.95 points or 4.48% from its previous closing of Rs. 535.05 on the BSE.
The scrip opened at Rs. 543.00 and has touched a high and low of Rs. 564.95 and Rs. 541.35 respectively. So far 38955 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 724.55 on 02-Sep-2024 and a 52 week low of Rs. 382.05 on 15-Apr-2024.
Last one week high and low of the scrip stood at Rs. 601.10 and Rs. 502.40 respectively. The current market cap of the company is Rs. 13545.70 crore.
The promoters holding in the company stood at 38.85%, while Institutions and Non-Institutions held 35.44% and 25.72% respectively.
Granules India has received EU GMP certificate for Active Pharmaceutical Ingredients (APIs) and Finished Dosages (FDs) for its Unit V facility located at Visakhapatnam, Andhra Pradesh. The EU (National Centre for Public Health and Pharmacy, Hungary) Authority conducted the audit of the facility in the month of November 2024. This facility manufactures APIs & formulations of oncology and non-oncology products.
Granules India is manufacturer and supplier of pharmaceutical products. Its products include active pharmaceutical ingredients like tablets, caplets, rapid release, pharmaceutical, formulation intermediates (PFI) and Finished Dosages.
